This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
moving-average-crossover: Archive
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ARCTNegative Net Change ALKSPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Strength Seen in Paladin (PALAF): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Paladin (PALAF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PALAFNegative Net Change NHYDYPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
FHTXPositive Net Change PRMENegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TARSPositive Net Change BCYCPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Genuine Parts (GPC) Moves 12.9% Higher: Will This Strength Last?
by Zacks Equity Research
Genuine Parts (GPC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GPCNegative Net Change DRVNNegative Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
DLocal (DLO) Moves 12.9% Higher: Will This Strength Last?
by Zacks Equity Research
DLocal (DLO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
DLONegative Net Change EEFTNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Meta Platforms (META) Surges 8.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Meta Platforms (META) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
METANegative Net Change NICENegative Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
Astrana Health, Inc. (ASTH) Surges 7.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Astrana Health, Inc. (ASTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ASTHNegative Net Change USPHNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Texas Roadhouse (TXRH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TXRHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Amplitude (AMPL) Moves 11.8% Higher: Will This Strength Last?
by Zacks Equity Research
Amplitude (AMPL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AMPLNegative Net Change QXONegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today